All In Biotech

Drug Trial Radar · NCT05957380

Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

Last checked: Nov 20, 2026Latest source record: Oct 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Mar 20, 2023

Primary completion

Sep 30, 2024

Study completion Sep 30, 2024

Sponsor

Lead sponsor
Dong-A ST Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multi-center, double-blind, active-controlled, randomized, parallel clinical study to evaluate the efficacy and safety of DA-2803 in chronic hepatitis B subjects

Conditions

  • Hepatitis B

Interventions

  • DA-2803Drug

    All participants are administered one tablet per day for 48 weeks

  • DA-2803-RDrug

    All participants are administered one tablet per day for 48 weeks

  • Placebo of DA-2803Drug

    All participants are administered one tablet per day for 48 weeks

  • Placebo of DA-2803-RDrug

    All participants are administered one tablet per day for 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HBV DNA(log10 IU/mL) changeTime frame: 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Catholic University of Korea, Seoul

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.